DermaSensor Secures $5M, Inks Four Major Deals to Scale AI Cancer Tech

MIAMI, FL – September 09, 2026 – In the world of medical technology, momentum is built on a foundation of clinical validation, regulatory approval, and commercial traction. Miami-based DermaSensor Inc. just sent one of the year’s clearest growth signals, announcing a multi-faceted strategy that combines fresh capital with a powerful new commercial infrastructure. The AI-powered skin cancer diagnostics company has closed a $5 million funding round and, in a parallel move, unveiled four major U.S. partnerships poised to dramatically accelerate the adoption of its groundbreaking device.

This dual announcement is more than just a standard business update; it's a meticulously executed playbook for scaling a novel medical device. By securing strategic capital while simultaneously unlocking key distribution, sales, and institutional channels, DermaSensor is moving aggressively to translate its technological edge into market dominance. The moves position the company to fundamentally alter how skin cancer—a condition affecting one in five Americans—is detected at the front lines of healthcare.

A Dual-Pronged Strategy for Scale

DermaSensor’s latest capital infusion consists of a $4 million Series B extension from institutional and strategic investors, complemented by over $1 million raised through a community investment round on the Wefunder platform. This hybrid approach is a telling signal in itself. While institutional backing provides a stamp of professional validation, the decision to open the round to the public at the same terms is a strategic masterstroke in community building and market activation.

“Our professional investor partners have supported us through every phase of building this new medical device category,” said Cody Simmons, Co-Founder and CEO of DermaSensor. “Opening the financing on Wefunder is about extending that ownership to the physicians and patients who are living the problem we're solving... We want the people closest to it to have a seat at the table.”

This isn't just about democratizing investment; it's about creating a grassroots army of advocates. With investment minimums as low as $250, the company is empowering the very people it aims to serve—primary care physicians and their patients—to become stakeholders in its success. In a market where trust and provider adoption are paramount, having potentially thousands of micro-investors championing the technology within their own networks could prove to be an invaluable, self-perpetuating growth engine. The move brings the company's total funding to $48 million, providing the financial runway needed to fuel its ambitious expansion.

Building a Nationwide Commercial Infrastructure

Capital without a clear path to market is merely potential. DermaSensor’s simultaneous announcement of four strategic partnerships demonstrates that its leadership understands this implicitly. Together, these agreements create a comprehensive commercial ecosystem designed to embed its device across the U.S. healthcare landscape.

First, an approved supplier relationship with Henry Schein, Inc., the world’s largest provider of healthcare solutions to office-based practitioners, opens a vast distribution channel. This partnership effectively places DermaSensor’s device on the shelf for a massive network of primary care practices, streamlining procurement and lowering the barrier to adoption for independent clinics and health systems alike.

Second, the company secured a customer partnership with an unnamed major U.S. healthcare institution that employs tens of thousands of providers. This move provides immediate, large-scale implementation and serves as powerful validation. Having a national-level health system integrate the device into its standard of care is a powerful testament to its clinical and economic value proposition, creating a flagship case study for others to follow.

Third, a commercial partnership with MedTech MedCare (MTMC), the largest medical device contract sales company in the U.S., provides the field expertise and 'boots on the ground' necessary to drive awareness and sales. With over 150 sales representatives, MTMC offers DermaSensor a seasoned, scalable sales force to educate providers and accelerate adoption, starting with a rollout in Texas and expanding to other states.

Finally, an exclusive reseller agreement with Medical Place for the U.S. Department of Veterans Affairs (VA) carves out a critical pathway into the federal healthcare system. This is particularly significant given that veterans experience skin cancer at three times the national rate. This partnership not only addresses a population with a high unmet need but also positions DermaSensor within one of the nation's largest integrated healthcare systems.

The Technology Behind the Momentum

This strategic and financial momentum is anchored by a powerful and validated technology. DermaSensor's handheld device uses Elastic Scattering Spectroscopy (ESS) and an AI algorithm to provide an immediate, objective risk assessment for suspicious skin lesions. For a primary care physician, this transforms a subjective visual check into a data-driven decision point.

The device’s clinical bona fides are impressive. In FDA pivotal studies involving over 1,000 patients, the device demonstrated 96% sensitivity across the three most common forms of skin cancer—melanoma, basal cell carcinoma, and squamous cell carcinoma. Perhaps more importantly for the healthcare system, it was shown to reduce the number of missed skin cancer referrals by more than 50%. This addresses two critical pain points: catching cancers earlier and reducing the burden of unnecessary referrals to specialists for benign lesions.

Crucially, DermaSensor holds a Class II De Novo clearance from the FDA, making it the first and only device cleared to provide a risk assessment for all three common skin cancers. This De Novo classification, reserved for novel devices without a market predicate, creates a significant regulatory moat and a powerful marketing advantage. Since its commercial launch two years ago, the device has already been used to evaluate over 45,000 lesions across hundreds of provider organizations, proving its utility in real-world clinical settings.

Market Context and Future Trajectory

DermaSensor's aggressive push comes at a time when healthcare is increasingly embracing AI-driven, point-of-care diagnostics. The goal is to move specialized capabilities out of the hospital and into the community, making healthcare more accessible, efficient, and proactive. By empowering primary care physicians—the gatekeepers of the healthcare system—to screen for skin cancer more effectively, DermaSensor is perfectly aligned with this macro trend.

The company’s ambitions are not limited to the United States. A CE Mark obtained in June 2026 has already paved the way for European expansion, supported by a strategic partnership with a large European distributor that also invested in the company's Series B round. With a stated goal of achieving $100 million in Annual Recurring Revenue (ARR) by 2031, DermaSensor is signaling its intent to build a global category leader. The combination of a novel funding model, a robust commercialization strategy, and a clinically validated, FDA-cleared technology provides a compelling blueprint for how to turn a promising innovation into a healthcare standard.